exchange chromatography (Pharmacia Fine Chemicals) by using a 0 -0.2 mol/L NaCl gradient in a stepwise elution with 15 mmol/L phosphate buffer, pH 7.2, at a flow rate of 10 mL/h. The dissociated Ig was incubated with the purified AST isoenzymes (s-AST 386 U/L, m-AST 986 U/L) in a ratio of 4:1 by volume at 25°C for 60 min, and the recombined enzyme-Ig complex was detected by immunoturbidimetry [11] . Immunoturbidimetry showed that the absorbances in tubes to which anti-IgM and the patient's IgM and s-AST had been added were higher than in tubes containing m-AST (Table 1 ). The results showed that the purified IgM was able to recombine with s-AST. These results show that the patient's increased serum AST was related to the presence of an s-AST-IgM--type complex.
Novel Reductant for Determination of Total Plasma
Homocysteine, Brian M. Gilfix, 1,2 * David W. Blank, 2 and David S. Rosenblatt 1 ( 1 Div. of Med. Genetics, 2 Div. of Clin. Biochem., Royal Victoria Hosp., 687 Pine Ave. W., Montreal, QC H3A 1A1, Canada; * author for correspondence: fax 514-843-1499, e-mail mcbg@musica.mcgill.ca) Homocysteine (Hcy), increasingly being recognized as a risk factor for vascular disease [1] , is found primarily in plasma in the form of homocystine and mixed disulfides, both protein-bound and unbound; total Hcy (tHcy) is the sum of all Hcy species obtained after quantitative reduction. Several methods are currently used to measure tHcy in plasma, including GC/MS, ion-exchange chromatography, and HPLC [2] . In one of the most popular HPLC techniques, any homocystine and homocysteine-mixed disulfides present are reduced with tri-butyl phosphine (TBP) to Hcy, which is subsequently derivatized with ammonium 7-fluorobenzo-2-oxa-1,3-diazole-4-sulfonate (SBD-F) to produce a fluorescent product [3, 4] . TBP has a highly disagreeable odor and is poorly soluble in water so that it must be dissolved in dimethylformamide for use, both of which properties hinder the routine use of TBP in a clinical laboratory. Here, we call attention to a newer phosphine reagent, tris(2-carboxylethyl) phosphine (TCEP), which is nonvolatile, stable, and soluble in aqueous solution and thus is more suitable for routine use.
We have therefore modified the method of Ubbick and Vermaak [4] as follows. First, add 9 L of 100 g/L TCEP (aq) (Pierce Chemical Co., Rockford, IL) to 90 L of plasma, mix, and allow to react for 30 min at room temperature. Then, add 90 L of 100 g/L trichloroacetic acid containing 1 mmol/L EDTA. After centrifuging the sample for 10 min at 13 000g, add 100 L of the supernatant to a tube containing 20 L of 1.55 mol/L NaOH, 250 L of 0.125 mol/L borate buffer containing 4 mmol/L EDTA, pH 9.5, and 100 L of SBD-F (Wako Chemicals USA, Richmond, VA), 1 g/L in the borate buffer. After mixing, incubate the solution for 1 h at 60°C, let cool to room temperature, and inject 20 L of this onto a C 18 column to run at a flow rate of 1.5 mL/min [4] . Figure 1 shows the relation between the Hcy determined after reduction with TCEP as a function of that determined after reduction with TBP in aliquots of the same plasma samples [5] . All plasma samples were obtained in accordance with the guidelines of the research ethics board at our institution.
For the Hcy determinations with TCEP, Hcy calibrators were prepared in isotonic saline (NaCl 9 g/L), the as-signed concentration being based on a molar absorptivity for Hcy of 397 L mol Ϫ1 cm Ϫ1 at 244 nm. These saline calibrators were chromatographed and used to prepare a calibration curve from which the Hcy concentrations in the plasma samples were calculated according to peak heights. When Hcy was added to plasma samples, recovery was 100% (results not shown). Hcy determinations in plasma with TBP were performed at the Institut de Recherches Cliniques de Montreal (by L.-J. Fortin, whom we thank for these determinations). For the Hcy determinations done with TBP, Hcy calibrators were prepared in plasma, and the Hcy concentrations were based on peak areas [5] .
The correlation coefficient between the results obtained with the two different reductants is 0.988, although the TCEP method yields values ϳ21% higher. This may reflect simple differences in methodology-e.g., the calculation of results (peak height vs peak area), the calibration matrix (saline vs plasma), or quantification of the calibrators (molar absorptivity vs dry weight, respectively)-or differences in the efficiency of reduction with TCEP, and suggests the necessity of developing an interlaboratory standardization procedure. The 5th, 50th, and 95th percentiles for plasma tHcy determined with TCEP reduction for a population of 30 individuals (15 men, 15 women; mean Ϯ SD ages, 36.9 Ϯ 10.6 years) were 5.2, 9.8, and 14.9 mol/L, respectively. Usable values can be produced from as little as 15 L of plasma. The TCEP solution can be stored at Ϫ20°C and is stable to freezing and thawing. Current workplace drug-testing programs require reporting positive results only if the gas chromatography/mass Fig. 1 . Total plasma homocysteine measured after reduction with TCEP as calculated by using peak height vs the concentration measured after reduction with TBP as calculated by using peak area in aliquots of the same plasma sample.
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The equation of the line is y ϭ Ϫ0.088 ϩ 1.21x, r ϭ 0.988. S y͉x , the standard deviation of residuals for this line, is 0.50.
